BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.
GlobalData on MSN

BioInvent’s mAb plus Keytruda boosts ORR in mid-stage ovarian cancer trial

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
PharmiWeb

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
Yahoo Finance

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

RAHWAY, N.J., October 20, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival ...
Nasdaq

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
CURE

Padcev/Keytruda Combo Extends Survival in Muscle-Invasive Bladder Cancer

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.
PharmiWeb

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

First positive study for KEYTRUDA as adjuvant therapy for these patients RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the ...
PharmaTimes

Merck pauses Keytruda studies to assess patient deaths

Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns. Merck has paused new ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Co…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Cure Today

First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma

CytomX Therapeutics is testing CX-801 with Keytruda in a phase 1 trial for metastatic melanoma, focusing on safety and clinical activity. The trial is conducted at UCSF and the University of ...
Daily Mail

Lung cancer breakthrough as Merck's immunotherapy drug Keytruda sets new five-year survival rate for patients with the disease in advanced stages

Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major ...